202 related articles for article (PubMed ID: 30055223)
1. Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?
Singh SK; Mahler HC; Hartman C; Stark CA
J Pharm Sci; 2018 Nov; 107(11):2735-2741. PubMed ID: 30055223
[TBL] [Abstract][Full Text] [Related]
2. Considerations for the Use of Polysorbates in Biopharmaceuticals.
Jones MT; Mahler HC; Yadav S; Bindra D; Corvari V; Fesinmeyer RM; Gupta K; Harmon AM; Hinds KD; Koulov A; Liu W; Maloney K; Wang J; Yeh PY; Singh SK
Pharm Res; 2018 May; 35(8):148. PubMed ID: 29797101
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin.
Steele RH; Limaye S; Cleland B; Chow J; Suranyi MG
Nephrology (Carlton); 2005 Jun; 10(3):317-20. PubMed ID: 15958049
[TBL] [Abstract][Full Text] [Related]
4. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
[TBL] [Abstract][Full Text] [Related]
5. Biologic excipients: Importance of clinical awareness of inactive ingredients.
Ionova Y; Wilson L
PLoS One; 2020; 15(6):e0235076. PubMed ID: 32584876
[TBL] [Abstract][Full Text] [Related]
6. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.
Price KS; Hamilton RG
Allergy Asthma Proc; 2007; 28(3):313-9. PubMed ID: 17619560
[TBL] [Abstract][Full Text] [Related]
7. Anaphylaxis Due to the Excipient Polysorbate 80.
Palacios Castaño MI; Venturini Díaz M; Lobera Labairu T; González Mahave I; Del Pozo Gil MD; Blasco Sarramián A
J Investig Allergol Clin Immunol; 2016; 26(6):394-396. PubMed ID: 27996954
[No Abstract] [Full Text] [Related]
8. Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations.
Katz JS; Chou DK; Christian TR; Das TK; Patel M; Singh SN; Wen Y
J Pharm Sci; 2022 Apr; 111(4):919-932. PubMed ID: 34883096
[TBL] [Abstract][Full Text] [Related]
9. Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.
Yarbrough M; Hodge T; Menard D; Jerome R; Ryczek J; Moore D; Baldus P; Warne N; Ohtake S
J Pharm Sci; 2019 Apr; 108(4):1631-1635. PubMed ID: 30502482
[TBL] [Abstract][Full Text] [Related]
10. [Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80].
Pantín C; Letellez J; Calzas J; Mohedano E
Farm Hosp; 2018 Jan; 42(1):27-28. PubMed ID: 29306312
[No Abstract] [Full Text] [Related]
11. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic understanding of metal-catalyzed oxidation of polysorbate 80 and monoclonal antibody in biotherapeutic formulations.
Bensaid F; Dagallier C; Authelin JR; Audat H; Filipe V; Narradon C; Guibal P; Clavier S; Wils P
Int J Pharm; 2022 Mar; 615():121496. PubMed ID: 35074436
[TBL] [Abstract][Full Text] [Related]
13. Rational design to biologics development: The polysorbates point of view.
Brovč EV; Mravljak J; Šink R; Pajk S
Int J Pharm; 2020 May; 581():119285. PubMed ID: 32240804
[TBL] [Abstract][Full Text] [Related]
14. Injection site reactions with the use of biological agents.
Thomaidou E; Ramot Y
Dermatol Ther; 2019 Mar; 32(2):e12817. PubMed ID: 30637967
[TBL] [Abstract][Full Text] [Related]
15. Novel markers to track oxidative polysorbate degradation in pharmaceutical formulations.
Dahotre S; Tomlinson A; Lin B; Yadav S
J Pharm Biomed Anal; 2018 Aug; 157():201-207. PubMed ID: 29803911
[TBL] [Abstract][Full Text] [Related]
16. Putative Phospholipase B-Like 2 is Not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products.
Zhang S; Xiao H; Goren M; Burakov D; Chen G; Li N; Tustian A; Adams B; Mattila J; Bak H
J Pharm Sci; 2020 Sep; 109(9):2710-2718. PubMed ID: 32534029
[TBL] [Abstract][Full Text] [Related]
17. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases.
Zhang S; Riccardi C; Kamen D; Reilly J; Mattila J; Bak H; Xiao H; Li N
Pharm Res; 2022 Jan; 39(1):75-87. PubMed ID: 34981317
[TBL] [Abstract][Full Text] [Related]
18. An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity.
Limaye S; Steele RH; Quin J; Cleland B
J Allergy Clin Immunol; 2002 Sep; 110(3):530. PubMed ID: 12209107
[No Abstract] [Full Text] [Related]
19. Impact of Stainless Steel Exposure on the Oxidation of Polysorbate 80 in Histidine Placebo and Active Monoclonal Antibody Formulation.
Gopalrathnam G; Sharma AN; Dodd SW; Huang L
PDA J Pharm Sci Technol; 2018; 72(2):163-175. PubMed ID: 29343621
[TBL] [Abstract][Full Text] [Related]
20. Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation.
Yue L; Yan Z; Li H; Liu X; Sun P
Eur J Pharm Biopharm; 2020 Jan; 146():73-83. PubMed ID: 31811896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
